NASDAQ:INDP

Indaptus Therapeutics (INDP) Stock Forecast, Price & News

$2.78

+0.29 (+11.65%)

(As of 09/26/2023 ET)

Compare

Today's Range: $2.52
▼
$2.85
50-Day Range: $1.75
▼
$3.95
52-Week Range: $1.25
▼
$4.08

Volume: 24,648 shs
Average Volume: 25,028 shs
Market Capitalization: $23.35 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.00

Indaptus Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 331.7% Upside
$12.00 Price Target
Short Interest: Healthy
0.39% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.65
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$142,052 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.92) to ($1.88) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.66 out of 5 stars

Medical Sector

118th out of 963 stocks

Pharmaceutical Preparations Industry

36th out of 450 stocks

3.5

Analyst's Opinion

Consensus Rating
Indaptus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.00, Indaptus Therapeutics has a forecasted upside of 331.7% from its current price of $2.78.
Amount of Analyst Coverage
Indaptus Therapeutics has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.39% of the float of Indaptus Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Indaptus Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Indaptus Therapeutics has recently decreased by 51.61%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Indaptus Therapeutics does not currently pay a dividend.
Dividend Growth
Indaptus Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for INDP.

2.6

News and Social Media Coverage

News Sentiment
Indaptus Therapeutics has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Indaptus Therapeutics this week, compared to 0 articles on an average week.
MarketBeat Follows
4 people have added Indaptus Therapeutics to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Indaptus Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $142,052.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
27.10% of the stock of Indaptus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 21.24% of the stock of Indaptus Therapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Indaptus Therapeutics are expected to grow in the coming year, from ($1.92) to ($1.88) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Indaptus Therapeutics is -1.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Indaptus Therapeutics is -1.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Indaptus Therapeutics has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Indaptus Therapeutics (NASDAQ:INDP) Stock

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

INDP Price History

30 days | 90 days | 365 days | Advanced Chart

INDP Stock News Headlines

September 26, 2023 | finance.yahoo.com

Registration Is Now Open For Tribe Public’s Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics’ CEO On Friday, September 29, 2023

September 22, 2023 | americanbankingnews.com

HC Wainwright Reiterates Buy Rating for Indaptus Therapeutics (NASDAQ:INDP)

September 27, 2023 | Edge On The Street (Ad)

Is Gold Really Boring?

Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.

September 20, 2023 | americanbankingnews.com

Indaptus Therapeutics (NASDAQ:INDP) Trading Up 7.3%

September 19, 2023 | finance.yahoo.com

Indaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20

September 6, 2023 | finance.yahoo.com

Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 29, 2023 | finance.yahoo.com

Favourable Signals For Indaptus Therapeutics: Numerous Insiders Acquired Stock

August 14, 2023 | finance.yahoo.com

Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

September 27, 2023 | Edge On The Street (Ad)

Is Gold Really Boring?

August 11, 2023 | markets.businessinsider.com

Maxim Group Remains a Buy on Indaptus Therapeutics (INDP)

August 10, 2023 | finance.yahoo.com

Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20

August 7, 2023 | finance.yahoo.com

Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer

May 31, 2023 | finance.yahoo.com

Indaptus Therapeutics to Present at the Jefferies Healthcare Conference 2023

May 31, 2023 | finance.yahoo.com

Indaptus Therapeutics to Present at the Jefferies Healthcare Conference 2023

May 9, 2023 | finance.yahoo.com

Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform

May 4, 2023 | markets.businessinsider.com

What 4 Analyst Ratings Have To Say About Indaptus Therapeutics

May 4, 2023 | msn.com

HC Wainwright & Co. Reiterates Indaptus Therapeutics (INDP) Buy Recommendation

May 2, 2023 | finance.yahoo.com

We Think Indaptus Therapeutics (NASDAQ:INDP) Needs To Drive Business Growth Carefully

May 1, 2023 | benzinga.com

Indaptus Therapeutics' Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit

May 1, 2023 | finance.yahoo.com

Indaptus Therapeutics’ Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit

April 20, 2023 | finance.yahoo.com

Indaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023

April 19, 2023 | msn.com

Indaptus Therapeutics Says Antitumor Platform Demonstrates Preclinical Efficacy Across Cancer Indications

April 19, 2023 | finance.yahoo.com

Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

April 19, 2023 | finance.yahoo.com

UPDATE -- Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

April 17, 2023 | finance.yahoo.com

Indaptus Therapeutics Receives Brazilian Patent Allowance for Decoy Platform

March 22, 2023 | finance.yahoo.com

Quite a few insiders invested in Indaptus Therapeutics, Inc. (NASDAQ:INDP) last year which is positive news for shareholders

March 22, 2023 | finance.yahoo.com

Indaptus Therapeutics to Present at the Investor Summit Conference

See More Headlines

Receive INDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Indaptus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

INDP Company Calendar

Last Earnings: 8/14/2023
Today: 9/27/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:INDP
CUSIP: N/A
CIK: 1857044
Web: intecpharma.com
Phone: (646) 427-2727
Fax: 972-2586-9176
Employees: 6
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $12.00
High Stock Price Forecast: $12.00
Low Stock Price Forecast: $12.00
Forecasted Upside/Downside: +331.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.76)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,320,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -63.56%
Return on Assets: -57.05%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.45
Quick Ratio: 9.45

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.98 per share
Price / Book: 0.93

Miscellaneous

Outstanding Shares: 8,400,000
Free Float: 6,124,000
Market Cap: $23.35 million
Optionable: Not Optionable
Beta: 1.04

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. Jeffrey A. Meckler (Age 56)
CEO & Director
Comp: $888.32k

Mr. Walt Addison Linscott Esq. (Age 62)
Chief Operating Officer
Comp: $666.63k

Dr. Michael J. Newman Ph.D. (Age 67)
Founder, Chief Scientific Officer & Director

Mr. Nir Sassi (Age 47)
CFO, Sec. & Treasurer

Dr. Roger J. Waltzman M.B.A. (Age 55)
M.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

INDP Stock - Frequently Asked Questions

Should I buy or sell Indaptus Therapeutics stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Indaptus Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" INDP shares.
View INDP analyst ratings or view top-rated stocks.
What is Indaptus Therapeutics' stock price forecast for 2023?: 1 equities research analysts have issued 12-month price objectives for Indaptus Therapeutics' stock. Their INDP share price forecasts range from $12.00 to $12.00. On average, they anticipate the company's stock price to reach $12.00 in the next year. This suggests a possible upside of 331.7% from the stock's current price.
View analysts price targets for INDP or view top-rated stocks among Wall Street analysts.
How have INDP shares performed in 2023?: Indaptus Therapeutics' stock was trading at $1.45 on January 1st, 2023. Since then, INDP shares have increased by 91.7% and is now trading at $2.78.
View the best growth stocks for 2023 here.
When is Indaptus Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our INDP earnings forecast.
How were Indaptus Therapeutics' earnings last quarter?: Indaptus Therapeutics, Inc. (NASDAQ:INDP) released its quarterly earnings data on Monday, August, 14th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.19.

What is Indaptus Therapeutics' stock symbol?: Indaptus Therapeutics trades on the NASDAQ under the ticker symbol "INDP."
Who are Indaptus Therapeutics' major shareholders?: Indaptus Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Investment House LLC (1.29%) and Strategy Asset Managers LLC (0.54%). Insiders that own company stock include Boyan Vesselinov Litchev, Glen R Anderson, Jeffrey A Meckler, Michael James Newman and Walt Addison Linscott.
View institutional ownership trends.
How do I buy shares of Indaptus Therapeutics?: Shares of INDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Indaptus Therapeutics' stock price today?: One share of INDP stock can currently be purchased for approximately $2.78.
How much money does Indaptus Therapeutics make?: Indaptus Therapeutics (NASDAQ:INDP) has a market capitalization of $23.35 million. The company earns $-14,320,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis.
How can I contact Indaptus Therapeutics?: Indaptus Therapeutics' mailing address is 12 Hartom Street, Har Hotzvim, Jerusalem 777512. The official website for the company is intecpharma.com. The company can be reached via phone at (646) 427-2727, via email at will.oconnor@sternir.com, or via fax at 972-2586-9176.

This page (NASDAQ:INDP) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial